ROARABLE // PRO
GLOBAL DESKS // NYC --:--:-- NYSE
US TAPE
ROAR ▸
COMP <GO>

PGEN vs SUPN // EV/EBITDA & P/E VALUATION

Precigen Inc. (NASDAQ) VS. Supernus Pharmaceuticals Inc. (NASDAQ) • 15-METRIC TALLY: PGEN 2 — SUPN 6
■ METRIC PARITY
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (PGEN VS. SUPN) EMERALD CELL = QUANTITATIVE EDGE
INSTITUTIONAL METRIC PGEN SUPN SPREAD (A - B) ADVANTAGE DEDICATED URL
Gross Profit Margin — 89.60% — TIE /gross-margins <GO>
Return on Invested Capital (ROIC) -35.00% -4.50% -30.50 SUPN /roic <GO>
EV/EBITDA & P/E Valuation ACTIVE — — — TIE /valuation <GO>
Free Cash Flow Yield -3.78% 1.89% -5.67 SUPN /fcf-yield <GO>
Operating Margin -60.00% -8.70% -51.30 SUPN /operating-margins <GO>
Net Profit Margin -60.00% -5.40% -54.60 SUPN /net-margins <GO>
Revenue Growth (YoY) 146.70% 8.60% +138.10 PGEN /revenue-growth <GO>
Dividend Yield & FCF Payout Safety 0.00% 0.00% 0.00 TIE /dividend-safety <GO>
Altman Z-Score & Debt/Equity — 4.84 — TIE /balance-sheet <GO>
Piotroski F-Score Quality 3/9 7/9 -4.00 SUPN /piotroski-score <GO>
Options Implied Move & Put/Call Skew — — — TIE /options-implied-move <GO>
RSI-14 & 200D SMA Momentum 50.5 51.1 -0.60 SUPN /rsi-technicals <GO>
10Y Yield & FRED Macro Beta — 0.88 — TIE /macro-sensitivity <GO>
Forward P/E Multiple — 22.0x — TIE /forward-pe <GO>
Enterprise Scale & Market Cap $2.48B $2.44B $43.5M PGEN /market-cap <GO>
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
FISCAL YEAR PGEN REV SUPN REV PGEN GROSS % SUPN GROSS % PGEN FCF SUPN FCF
FY 2025 $9.7M $719.0M — 89.6% -$89.8M $46.0M
FY 2024 $3.9M $661.8M — 88.2% -$76.8M $171.2M
FY 2023 $6.2M $607.5M — — -$66.9M $83.7M
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
PGEN // BETA —
SUPN // BETA 0.88